Translational precision medicine: an industry perspective

被引:0
作者
Dominik Hartl
Valeria de Luca
Anna Kostikova
Jason Laramie
Scott Kennedy
Enrico Ferrero
Richard Siegel
Martin Fink
Sohail Ahmed
John Millholland
Alexander Schuhmacher
Markus Hinder
Luca Piali
Adrian Roth
机构
[1] Novartis Institutes for BioMedical Research,Department of Pediatrics I
[2] University of Tübingen,undefined
[3] Novartis Institutes for BioMedical Research,undefined
[4] Novartis Precision Medicine,undefined
[5] Reutlingen University,undefined
[6] Roche Innovation Center Basel,undefined
来源
Journal of Translational Medicine | / 19卷
关键词
Translational medicine; Precision medicine; Drug development; Biomarkers; Multi-omics; Modeling; Artificial intelligence; Pharmaceutical industry; Digital biomarkers; Companion diagnostics;
D O I
暂无
中图分类号
学科分类号
摘要
In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.
引用
收藏
相关论文
共 654 条
[31]  
Shahzad A(2019)Predicting health and life span with the deep plasma proteome Nat Med 25 1815-280
[32]  
Don G(2016)Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases Adv Genet 93 147-563
[33]  
Cohrs RJ(2017)Multi-omics approaches to disease Genome Biol. 18 83-521
[34]  
Shakhnovich V(2011)Network medicine: a network-based approach to human disease Nat Rev Genet 12 56-2271
[35]  
Shih HP(2017)Network propagation: a universal amplifier of genetic associations Nat Rev Genet 18 551-1892
[36]  
Zhang X(2015)Personalized medicine: time for one-person trials Nature 520 609-102
[37]  
Aronov AM(2002)Network genomics–a novel approach for the analysis of biological systems in the post-genomic era Mol Biol Rep 29 265-370
[38]  
Frank R(2012)How advancement in biological network analysis methods empowers proteomics Proteomics 12 550-102
[39]  
Hargreaves R(2012)Systems pharmacology: network analysis to identify multiscale mechanisms of drug action Annu Rev Pharmacol Toxicol 52 505-362
[40]  
Kaur R(2019)Identification of specific pre-analytical quality control markers in plasma and serum samples Anal Methods-Uk 11 2259-146